FindTrial
Sign In

A Non-Inferiority Study of Remimazolam versus Propofol in ERCP

A prospective observational study of the effect of sedative drug (Remimazolam or Propofol) in patients undergoing endoscopic retrograde cholangiopancreatography

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0008459
Enrollment
110
Registered
2023-05-22
Start date
2022-08-23
Completion date
Unknown
Last updated
2023-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Inha University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) > 19 years old, (2) scheduled for a diagnostic or therapeutic ERCP, (3) patients who have provided informed consent for voluntary participation in research

Exclusion criteria

Exclusion criteria: (1) Patients incapable of endoscopic retrograde cholangiopancreatography (2) Patients who did not agree to participate in the study (3) Patients unable to administer Remimazolam or propofol

Design outcomes

Primary

MeasureTime frame
The primary endpoint was a composite of successful completion of the procedure and no requirement for rescue medication.—

Secondary

MeasureTime frame
The secondary endpoints included sedation efficacy, recovery time, and adverse events.—

Countries

Korea, Republic of

Contacts

Public ContactJungnam Lee

Inha University Hospital

gallary801105@gmail.com+82-32-890-2114

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026